MedPath

Prospective observational study of relapsed and refractory pediatric acute lymphoblastic leukemia

Not Applicable
Conditions
acute lymphoblastic leukemia
Registration Number
JPRN-UMIN000019878
Lead Sponsor
Japanese Pediatric Leukemia/Lymphoma Study Group
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
76
Inclusion Criteria

Not provided

Exclusion Criteria

None

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
2 year EFS in all cases, in subgroups according to risk classification in 1st relapse cases, or numbers of relapse. Odd ratio in reinduction rate between clofarabine regimens and other regimens. Correlation between results (IC50 values) of in vitro drug sensitivity tests and reinduction rate.
Secondary Outcome Measures
NameTimeMethod
2 year OS in all cases, or in subgroups according to risk classification in 1st relapse cases or numbers of relapse. 2nd progression free survival rate. Reinduction rate. Odds ratio in EFS between clofarabine regimens and other regimens. Odds ratio in OS between clofarabine regimens and other regimens. OS according to regimens or drugs used in reinduction therapy. Correlation between results (IC50 values) of in vitro drug sensitivity tests and reinduction rate in patients treated by clofarabine.
© Copyright 2025. All Rights Reserved by MedPath